Home >Current Issue

Volume: 9, Issue: 8, August, 2019
DOI: 10.7324/JAPS.2019.90802



Research Article

Outcomes of the patients of heart failure with reduced ejection fraction receiving inotropic support in initial 6 hours: Insights from Manipal Heart Failure Registry

Ajit Singh1, Sheetal Chauhan2, Ganesh Paramasivam1, Tom Devasia1, Yeshwanth Rao3, Prasad Narayana Shetty1, Navaneeth Amin1, Deepak Uppunda1, Hashir Kareem1

  Author Affiliations


Abstract

Heart failure (HF) is responsible for 1.8 million admissions annually in India with an additional burden of mortality and re-hospitalizations. Positive inotropes with multiple mechanisms, such as dopamine and levosimendan, are being used for more than three decades to treat the patients of acute HF with reduced ejection fraction (HFrEF). This study compared the outcomes of the dopamine and the levosimendan up to 180 days. We have selected the patients from Manipal Heart Failure Registry who were diagnosed to have HFrEF (left ventricular EF less than 50%) and were initiated on either dopamine or levosimendan in first 6 hours of hospitalization. The study included a total of 187 patients; among them, 120 patients were analyzed in the dopamine group, and 67 patients in the levosimendan group. Dopamine was initiated as intravenous infusion with the dose of 2.5 microgram/kilogram/minute (mcg/kg/minute) and up-titrated up to 10 mcg/kg/minute. Levosimendan was also administered intravenously with a dose of 0.1 mcg/ kg/minute and up-titrated up to 0.4 mcg/kg/minute. The primary outcomes include a composite of all-cause mortality and re-hospitalization at 30-days and 180-days follow-ups. The in-hospital mortality, 30-days mortality and 180-days mortality, and composite outcomes were noted higher in levosimendan treated patients even after matched demographic parameters (age and gender) and comparable comorbidities and risk factors, i.e., smoking, alcohol consumption, hypertension, diabetes mellitus, and atrial fibrillation. However, reduced EF, raised serum creatinine, procalcitonin, and N-terminal pro b-type natriuretic peptide levels and high use of digoxin were noticed in levosimendan group during the initial period of index-hospitalization and these can be considered as confounding factors for future studies.

Keywords:

Heart failure, inotropes, mortality; myocardial contractility, MHFR, re-hospitalizations.



Citation: Singh A, Chauhan S, Paramasivam G, Devasia T, Rao Y, Shetty PR, Amin N, Uppunda D, Kareem H. Outcomes of the patients of heart failure with reduced ejection fraction receiving inotropic support in initial 6 hours: Insights from Manipal Heart Failure Registry. J Appl Pharm Sci, 2019; 9(08):011–017.


Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Aidonidis G, Kanonidis I, Koutsimanis V, Neumann T, Erbel R, Sakadamis G. Efficiency and Safety of Prolonged Levosimendan Infusion in Patients with Acute Heart Failure. Cardiol Res Pract. 2011;2011:1-6. https://doi.org/10.4061/2011/342302

Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, Sihorsch K, Avgeropoulou E, Weber T, Dimopoulos L, Ulmer H, Poelzl G. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail, 2014; 16(8):898-906. https://doi.org/10.1002/ejhf.118

Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol, 2005; 96(6):47-58. https://doi.org/10.1016/j.amjcard.2005.07.021

Bistola V, Chioncel O. Inotropes in acute heart failure. Contin Cardiol Educ, 2017; 3(3):107-16. https://doi.org/10.1002/cce2.59

Braunwald E. The war against heart failure: the Lancet lecture. Lancet, 2015; 385(9970):812-24. https://doi.org/10.1016/S0140-6736(14)61889-4

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA, 2013; 310(23):2533-43. https://doi.org/10.1001/jama.2013.282190

Comín-Colet J, Manito N, Segovia-Cubero J, Delgado J, García Pinilla JM, Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, Gonzalez-Vilchez F, Lambert-Rodríguez JL, Grau M, Bruguera J; LION-HEART Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail, 2018; 20(7):1128-36. https://doi.org/10.1002/ejhf.1145

De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J, 2006; 27(16):1908-20. https://doi.org/10.1093/eurheartj/ehi875

Dzhaiani NA, Kositsyna IV, Gnidkina NA, Tereshchenko SN. Efficacy of levosimendan vs dopamine in patients with resistant cardiac failure. Terapevt Arkh, 2011; 83(6):53-9.

Felker GM, O'connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J, 2001; 142(3):393-401. https://doi.org/10.1067/mhj.2001.117606

Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol, 2014; 63(20):2069-78. https://doi.org/10.1016/j.jacc.2014.01.016

Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, Skoularigis J, Westermann D, Tschöpe C, Triposkiadis F. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail, 2010; 16(12):922-30. https://doi.org/10.1016/j.cardfail.2010.07.246

Guha S, Harikrishnan S, Ray S, Sethi R, Ramakrishnan S, Banerjee S, Bahl VK, Goswami KC, Banerjee AK, Shanmugasundaram S, Kerkar PG, Seth S, Yadav R, Kapoor A, Mahajan AU, Mohanan PP, Mishra S, Deb PK, Narasimhan C, Pancholia AK, Sinha A, Pradhan A, Alagesan R, Roy A, Vora A, Saxena A, Dasbiswas A, Srinivas BC, Chattopadhyay BP, Singh BP, Balachandar J, Balakrishnan KR, Pinto B, Manjunath CN, Lanjewar CP, Jain D, Sarma D, Paul GJ, Zachariah GA, Chopra HK, Vijayalakshmi IB, Tharakan JA, Dalal JJ, Sawhney JPS, Saha J, Christopher J, Talwar KK, Chandra KS, Venugopal K, Ganguly K, Hiremath MS, Hot M, Das MK, Bardolui N, Deshpande NV, Yadava OP, Bhardwaj P, Vishwakarma P, Rajput RK, Gupta R, Somasundaram S, Routray SN, Iyengar SS, Sanjay G, Tewari S, G S, Kumar S, Mookerjee S, Nair T, Mishra T, Samal UC, Kaul U, Chopra VK, Narain VS, Raj V, Lokhandwala Y. CSI position statement on management of heart failure in India. Indian Heart J, 2018; 70:S1-72. https://doi.org/10.1016/j.ihj.2018.11.002

Gustafsson F, Guarracino F, Schwinger RH. The inodilator levosimendan as a treatment for acute heart failure in various settings. Eur Heart J Suppl, 2017; 19(suppl_C):C2-7. https://doi.org/10.1093/eurheartj/sux001

Huang X, Lei S, Zhu MF, Jiang RL, Huang LQ, Xia GL, Zhi YH. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B, 2013; 14(5):400-15. https://doi.org/10.1631/jzus.B1200290

Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, Mangschau A, Bjørnerheim R, Andersen GØ. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail, 2013; 15(5):565-72. https://doi.org/10.1093/eurjhf/hfs215

Mathieu S, Craig G. Levosimendan in the treatment of acute heart failure, cardiogenic and septic shock: a critical review. J Crit Care Med, 2011; 12(1):15-24. https://doi.org/10.1177/175114371101200106

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Survive Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA, 2007; 297(17):1883-91. https://doi.org/10.1001/jama.297.17.1883

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T; REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail, 2013; 1(2):103-11. https://doi.org/10.1016/j.jchf.2012.12.004

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2016; 18(8):891-975. https://doi.org/10.1002/ejhf.592

Tariq S, Aronow W. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci, 2015; 16(12):29060-8. https://doi.org/10.3390/ijms161226147

Tavares M, Andrade AC, Mebazaa A. Levosimendan use in several scenarios of acute heart failure. Arq Bras Cardiol, 2008; 90(3):231-5. https://doi.org/10.1590/S0066-782X2008000300012

Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, Skoularigis J, Antoniou CK, Chrysohoou C, Pitsavos C, Stefanadis C, Nastas J, Tsaknakis T, Mantziari L, Giannakoulas G, Karvounis H, Kalogeropoulos AP, Giamouzis G. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol, 2014; 172(1):115-21. https://doi.org/10.1016/j.ijcard.2013.12.276

Upadya S, Lee FA, Saldarriaga C, Verma S, Sedrakyan A, Nystrom K, Katz SD. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant, 2004; 23(4):466-72. https://doi.org/10.1016/S1053-2498(03)00203-1

Xing F, Hu X, Jiang J, Ma Y, Tang A. A meta-analysis of low-dose dopamine in heart failure. Int J Cardiol, 2016; 222:1003-11. https://doi.org/10.1016/j.ijcard.2016.07.262

Article Metrics

Similar Articles